BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28596252)

  • 1. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes.
    Cull AH; Rauh MJ
    J Leukoc Biol; 2017 Aug; 102(2):209-219. PubMed ID: 28596252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
    Matos A; Magalhães SMM; Rauh MJ
    Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS).
    Kotsianidis I; Bouchliou I; Nakou E; Spanoudakis E; Margaritis D; Christophoridou AV; Anastasiades A; Tsigalou C; Bourikas G; Karadimitris A; Tsatalas C
    Leukemia; 2009 Mar; 23(3):510-8. PubMed ID: 19020538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
    Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
    Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow niche in the myelodysplastic syndromes.
    Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
    Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.
    Gañán-Gómez I; Wei Y; Starczynowski DT; Colla S; Yang H; Cabrero-Calvo M; Bohannan ZS; Verma A; Steidl U; Garcia-Manero G
    Leukemia; 2015 Jul; 29(7):1458-69. PubMed ID: 25761935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myelodysplastic syndromes: preleukemic syndromes].
    Tassin F; Hermanne JP; Schaaf-Lafontaine N; Herens C; Thiry A; Paulus JM; Boniver J; Fillet G
    Rev Med Liege; 1998 Jun; 53(6):357-62. PubMed ID: 9713217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
    Steensma DP
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
    Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
    Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
    Malcovati L; Cazzola M
    Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.
    Sallman DA; Tanaka TN; List A; Bejar R
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):613-620. PubMed ID: 29025689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoiesis-related microRNA expression in myelodysplastic syndromes.
    Pons A; Nomdedeu B; Navarro A; Gaya A; Gel B; Diaz T; Valera S; Rozman M; Belkaid M; Montserrat E; Monzo M
    Leuk Lymphoma; 2009 Nov; 50(11):1854-9. PubMed ID: 19883312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sequential acquisition of mutations in myelodysplastic syndromes].
    Makishima H
    Rinsho Ketsueki; 2017; 58(10):1828-1837. PubMed ID: 28978821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes.
    Sallman DA; List A
    Blood; 2019 Mar; 133(10):1039-1048. PubMed ID: 30670444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innate immune signaling in the myelodysplastic syndromes.
    Starczynowski DT; Karsan A
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes.
    Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
    Int J Hematol; 1993 Aug; 58(1-2):53-61. PubMed ID: 8219112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.